Connecting proteins with drug-like compounds: Open source drug discovery workflows with BindingDB and KNIME

被引:12
|
作者
Nicola, George [1 ]
Berthold, Michael R. [2 ]
Hedrick, Michael P. [3 ]
Gilson, Michael K. [1 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA
[2] Univ Konstanz, Dept Comp & Informat Sci, D-78457 Constance, Germany
[3] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA USA
来源
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION | 2015年
基金
美国国家卫生研究院;
关键词
MAXIMUM COMMON SUBSTRUCTURE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PHOSPHOLIPASE A(2); SMALL MOLECULES; DATABASE; CLOPERASTINE; SIMILARITY; PLATFORM; COUGH; CLASSIFICATION;
D O I
10.1093/database/bav087
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Today's large, public databases of protein-small molecule interaction data are creating important new opportunities for data mining and integration. At the same time, new graphical user interface-based workflow tools offer facile alternatives to custom scripting for informatics and data analysis. Here, we illustrate how the large protein-ligand database BindingDB may be incorporated into KNIME workflows as a step toward the integration of pharmacological data with broader biomolecular analyses. Thus, we describe a collection of KNIME workflows that access BindingDB data via RESTful webservices and, for more intensive queries, via a local distillation of the full BindingDB dataset. We focus in particular on the KNIME implementation of knowledge-based tools to generate informed hypotheses regarding protein targets of bioactive compounds, based on notions of chemical similarity. A number of variants of this basic approach are tested for seven existing drugs with relatively ill-defined therapeutic targets, leading to replication of some previously confirmed results and discovery of new, high-quality hits. Implications for future development are discussed.
引用
收藏
页数:22
相关论文
共 24 条
  • [21] Virtual Screening of Small Drug-Like Compounds Stimulating the Enzymatic Activity of Kallikrein-Related Peptidase3 (KLK3)
    Ylikangas, Henna
    Mattsson, Johanna M.
    Stenman, Ulf-Hakan
    Koistinen, Hannu
    Poso, Antti
    Lahtela-Kakkonen, Maija
    CHEMMEDCHEM, 2016, 11 (18) : 2043 - 2049
  • [22] Tyrosine Kinase Syk Non-Enzymatic Inhibitors and Potential Anti-Allergic Drug-Like Compounds Discovered by Virtual and In Vitro Screening
    Villoutreix, Bruno O.
    Laconde, Guillaume
    Lagorce, David
    Martineau, Pierre
    Miteva, Maria A.
    Dariavach, Piona
    PLOS ONE, 2011, 6 (06):
  • [23] Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
    Duffy, Sandra
    Sykes, Melissa L.
    Jones, Amy J.
    Shelper, Todd B.
    Simpson, Moana
    Lang, Rebecca
    Poulsen, Sally-Ann
    Sleebs, Brad E.
    Avery, Vicky M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
  • [24] Molecular Property Diagnostic Suite for COVID-19 (MPDSCOVID-19): an open-source disease-specific drug discovery portal
    Priyadarsinee, Lipsa
    Jamir, Esther
    Nagamani, Selvaraman
    Mahanta, Hridoy Jyoti
    Kumar, Nandan
    John, Lijo
    Sarma, Himakshi
    Kumar, Asheesh
    Gaur, Anamika Singh
    Sahoo, Rosaleen
    Vaikundamani, S.
    Murugan, N. Arul
    Priyakumar, U. Deva
    Raghava, G. P. S.
    Bharatam, Prasad, V
    Parthasarathi, Ramakrishnan
    Subramanian, V.
    Sastry, G. Madhavi
    Sastry, G. Narahari
    GIGABYTE, 2024, 2024 : 1 - 17